Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ: TSHA ) with a Market Outperform and maintains $11 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.